• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

FDA approves belimumab for treatment of pediatric lupus nephritis

Article

This decision by the US Food and Drug Administration marks the first approved treatment for pediatric lupus nephritis.

The US Food and Drug Administration (FDA) has approved belimumab (Benlysta; GSK) for the treatment of lupus nephritis in pediatric patients aged 5 to 17 years who are receiving standard therapy. This decision marks the first treatment approved by the FDA for pediatric lupus nephritis.1

This approval expands upon the current US indication to now include both lupus and active lupus nephritis for pediatric patients.

Belimumab is a BLyS-specific inhibitor and human monoclonal antibody. While belimumab does not directly bind B cells, it does bind to soluble BLyS and inhibits the survival of B cells, such as autoreactive B cells. It also reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

Belimumab was first approved by the FDA in 2011 and is the first and only FDA-approved biologic for both systemic lupus erythematosus and lupus nephritis in over 50 years.1

“The long-term goal of lupus nephritis management in adults and children is to preserve renal function while minimizing treatment-related toxicities and associated morbidity,” said Herson Quinones, vice president of specialty and pipeline US medical affairs at GSK.

He added, “This [belimumab] approval highlights GSK’s commitment to bring treatment options to children living with lupus nephritis. This is another example of how GSK continues to get ahead of this burdensome disease by focusing on science and being grounded in over a decade of clinical experience.”

Reference:

GSK announces US FDA approval of Benlysta (Belimumab) for pediatric patients with active lupus nephritis. GSK US. July 27, 2022. Accessed July 28, 2022. https://us.gsk.com/en-us/media/press-releases/gsk-announces-us-fda-approval-of-benlysta-belimumab-for-pediatric-patients-with-active-lupus-nephritis/

Related Videos
Rupa Wong, MD | Image Credit: Rupa Wong, MD
Tina Tan, MD, FAAP, FIDSA, FPIDS, editor in chief, Contemporary Pediatrics, professor of pediatrics, Feinberg School of Medicine, Northwestern University, pediatric infectious diseases attending, Ann & Robert H. Lurie Children's Hospital of Chicago
John Bradley, MD
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Pfizer's infant RSV vaccine receives FDA Advisory Committee's support | Image Credit: Dr_Microbe - Image Credit: Dr_Microbe
Tina Tan, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.